FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics; it can be used for increasing or maintaining muscle mass. A combination is proposed, including ActRII receptor inhibitor, which is bimagrumab, and a chemotherapeutic agent, which is everolimus, wherein bimagrumab and everolimus are in separate pharmaceutical compositions. The use of the specified combination is also proposed for increasing or maintaining muscle mass in a subject having an age-related condition.
EFFECT: additive effect of a combination is provided in terms of increasing muscle mass.
4 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF REDUCING CACHEXIA ASSOCIATED WITH CANCER | 2014 |
|
RU2692785C1 |
| COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR | 2011 |
|
RU2585489C2 |
| COMPOSITIONS AND METHODS OF PULMONARY HYPERTENSION TREATMENT | 2017 |
|
RU2748278C2 |
| ANTIBODY AGAINST IGF-I RECEPTOR | 2018 |
|
RU2785305C2 |
| COMPOSITIONS AND METHODS FOR INCREASING BODY WEIGHT AND LEAN MUSCLE MASS USING LEPTIN RECEPTOR ANTAGONISTS, GDF8 AND ACTIVIN A | 2019 |
|
RU2818832C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| ONCOGENE NRF2 AND ITS USE | 2009 |
|
RU2486253C2 |
| USE OF COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT | 2006 |
|
RU2461630C2 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| USE OF TRYPTOPHAN METABOLITES FOR THE TREATMENT OF MUSCULAR ATROPHY | 2017 |
|
RU2806346C2 |
